Tirofiban improves outcome in patients with a non-ST elevation ACS and a positive serum tropinin I

In the PRISM trial, tirofiban significantly reduced the 30-day event rate in 629 patients with a non-ST elevation acute coronary syndrome (ACS) who had evidence of myocardial necrosis based upon a positive serum troponin I level (≥1 µg/L) (4.9 versus 13 percent for heparin). The significant benefit of tirofiban was seen in patients managed medically (hazard ratio 0.30) and in those undergoing revascularization (hazard ratio 0.37).